Advertisement
Singapore markets closed
  • Straits Times Index

    3,297.55
    -26.98 (-0.81%)
     
  • Nikkei

    38,814.56
    +94.09 (+0.24%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • FTSE 100

    8,159.74
    -3.93 (-0.05%)
     
  • Bitcoin USD

    67,205.74
    -1,016.53 (-1.49%)
     
  • CMC Crypto 200

    1,429.69
    +11.82 (+0.83%)
     
  • S&P 500

    5,419.10
    -14.64 (-0.27%)
     
  • Dow

    38,488.32
    -158.78 (-0.41%)
     
  • Nasdaq

    17,632.58
    -34.98 (-0.20%)
     
  • Gold

    2,343.20
    +25.20 (+1.09%)
     
  • Crude Oil

    78.89
    +0.27 (+0.34%)
     
  • 10-Yr Bond

    4.2210
    -0.0170 (-0.40%)
     
  • FTSE Bursa Malaysia

    1,607.32
    -2.85 (-0.18%)
     
  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     
  • PSE Index

    6,383.70
    -7.13 (-0.11%)
     

A Struggling Pfizer Looks for Help From a Wall Streeter

A Struggling Pfizer Looks for Help From a Wall Streeter

As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn’t recommended the stock in over a decade. But Andrew Baum has something Pfizer needs: oncology expertise.